Genesis Molecular AI

Genesis Molecular AI (formerly Genesis Therapeutics) is an AI-first drug discovery and development company headquartered in Burlingame, California. Founded in 2019, the company builds foundation models and an AI operating system — GEMS (Generative AI for Drug Discovery) — for small molecule drug design, integrating generative AI with physics-based modeling to identify potent, selective drug candidates against chemically complex targets at unprecedented speed. Its 3D diffusion foundation model Pearl achieves field-leading performance in drug-protein structure prediction. Genesis operates a fully integrated laboratory in San Diego and partners with major pharmaceutical companies to co-discover and co-develop medicines. The company raised a $200M Series B in 2023 and has partnerships with NVIDIA Healthcare and Incyte.